Compile Data Set for Download or QSAR
Report error Found 141 Enz. Inhib. hit(s) with all data for entry = 10864
TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575561(US11459339, Example 41 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.0320nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575599(US11459339, Example 60 | (1s,1's,3s,3's)-3,3'-((((...)
Affinity DataIC50: 0.0340nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575553(US11459339, Example 37 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.0400nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575483(US11459339, Example 2 | US11459339, Example 4)
Affinity DataIC50: 0.0640nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575498(US11459339, Example 80 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.0820nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575493(US11459339, Example 7 | N,N'-(2,2'-dimethyl-[1,1'-...)
Affinity DataIC50: 0.0960nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575609(US11459339, Example 65 | (2S,2S)-1,1'-(((((2,2'-di...)
Affinity DataIC50: 0.120nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575505(US11459339, Example 13 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.130nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575486(US11459339, Example 74 | N,N'-2,2'-dimethyl[1,1'-b...)
Affinity DataIC50: 0.140nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575511(US11459339, Example 16 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.140nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575517(US11459339, Example 19 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.150nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575585(US11459339, Example 53 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.150nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575520(US11459339, Example 91 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.160nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575481(US11459339, Example 1 | N,N′-(2,2′-dim...)
Affinity DataIC50: 0.170nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575601(US11459339, Example 61 | (2'S)-(((((2,2'-dimethyl-...)
Affinity DataIC50: 0.180nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575483(US11459339, Example 2 | US11459339, Example 4)
Affinity DataIC50: 0.180nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575485(US11459339, Example 3 | N,N'-(2,2'-dimethyl-[1,1'-...)
Affinity DataIC50: 0.200nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575602(US11459339, Example 132 | (3R,3'R)-1,1'-(((((2,2'-...)
Affinity DataIC50: 0.200nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575587(US11459339, Example 54 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.210nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575547(US11459339, Example 34 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.210nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575581(US11459339, Example 51 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.220nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575569(US11459339, Example 45 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.220nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575595(US11459339, Example 58 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.220nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575567(US11459339, Example 44 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.240nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575603(US11459339, Example 62 | (2S,2'S,4R,4'R)-1,1'-((((...)
Affinity DataIC50: 0.25nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575571(US11459339, Example 46 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.25nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575605(US11459339, Example 63 | (3S,3'S)-4,4'(((((2,2'-di...)
Affinity DataIC50: 0.25nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575543(US11459339, Example 32 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.270nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575573(US11459339, Example 47 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.270nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575548(US11459339, Example 105 | (2R,2'R)-2,2'-((((((2,2'...)
Affinity DataIC50: 0.270nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575533(US11459339, Example 27 | (2S,2'S)-1,1'-(((((2,2'-d...)
Affinity DataIC50: 0.280nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575523(US11459339, Example 22 | dimethyl 2,2'-((((((2,2'-...)
Affinity DataIC50: 0.280nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575499(US11459339, Example 10 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.280nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575563(US11459339, Example 42 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.280nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575565(US11459339, Example 43 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.290nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575559(US11459339, Example 40 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.290nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575484(US11459339, Example 73 | (3S,3'S)-3,3'-((((((2,2'-...)
Affinity DataIC50: 0.290nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575615(US11459339, Example 68 | N,N'-(2,2'-dimethyl-11,1'...)
Affinity DataIC50: 0.310nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575597(US11459339, Example 59 | (3S,3'S)-4,4'-((((((2,2'-...)
Affinity DataIC50: 0.310nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575575(US11459339, Example 48 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.310nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575525(US11459339, Example 23 | (2S,2'S)-2,2'-((((((2,2'-...)
Affinity DataIC50: 0.310nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575608(US11459339, Example 136 | (3S,3'S)-4,4'-((((((2,2'...)
Affinity DataIC50: 0.320nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575621(US11459339, Example 71 | (2R,2′R)-2,2′...)
Affinity DataIC50: 0.330nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575579(US11459339, Example 50 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.330nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575577(US11459339, Example 49 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.330nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575515(US11459339, Example 18 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.340nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575519(US11459339, Example 20 | dimethyl 2,2'-((((((2,2'-...)
Affinity DataIC50: 0.360nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575488(US11459339, Example 75 | (3R,3'R)-3,3'-((((((2,2'-...)
Affinity DataIC50: 0.360nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575518(US11459339, Example 90 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.360nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575489(US11459339, Example 5 | N,N'-(2,2'-dimethyl-[1,1'-...)
Affinity DataIC50: 0.360nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

Displayed 1 to 50 (of 141 total ) | Next | Last >>
Jump to: